Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive Sleepiness Due to Narcolepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Solriamfetol (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 10 Dec 2022 Results of pooled analysis from two phase 2 studies (NCT02806895, EudraCT 2015-003930-28, NCT02806908, EudraCT 2015-003931-36) published in the Neurology and Therapy
- 22 Apr 2021 Primary endpoint (Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) has been met according to the results presented at the 73rd Annual Meeting of the American Academy of Neurology
- 22 Apr 2021 Results assessing the effects of solriamfetol on on-road driving performance in participants with narcolepsy presented at the 73rd Annual Meeting of the American Academy of Neurology